###begin article-title 0
###xml 0 17 <span type="species:ncbi:10407">Hepatitis B virus</span>
Hepatitis B virus X protein and the estrogen receptor variant lacking exon 5 inhibit estrogen receptor signaling in hepatoma cells
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License () which permits unrestricted non-commerical use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin p 2
###xml 609 617 585 593 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 622 629 598 605 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 0 17 <span type="species:ncbi:10407">Hepatitis B virus</span>
###xml 19 22 <span type="species:ncbi:10407?0.9699783742526397">HBV</span>
###xml 129 132 <span type="species:ncbi:10407?0.9699783742526397">HBV</span>
###xml 182 185 <span type="species:ncbi:9606">men</span>
###xml 194 199 <span type="species:ncbi:9606">women</span>
###xml 292 295 <span type="species:ncbi:10407?0.9699783742526397">HBV</span>
###xml 398 406 <span type="species:ncbi:9606">patients</span>
###xml 430 438 <span type="species:ncbi:9606">patients</span>
Hepatitis B virus (HBV) X protein (HBx) is considered to play a role in the development of hepatocellular carcinoma (HCC) during HBV infection. HCC was shown to be more prevalent in men than in women. Estrogen, which exerts its biological function through estrogen receptor (ER), can inhibit HBV replication. ERDelta5, an ERalpha variant lacking exon 5, was found to be preferentially expressed in patients with HCC compared with patients with normal livers. Here, we report the biological role of ERDelta5 and a novel link between HBx and ERalpha signaling in hepatoma cells. ERDelta5 interacts with ERalpha in vitro and in vivo and functions as a dominant negative receptor. Both ERalpha and ERDelta5 associate with HBx. HBx decreases ERalpha-dependent transcriptional activity, and HBx and ERDelta5 have additive effect on suppression of ERalpha transactivation. The HBx deletion mutant that lacks the ERalpha-binding site abolishes the HBx repression of ERalpha. HBx, ERalpha and histone deacetylase 1 (HDAC1) form a ternary complex. Trichostatin A, a specific inhibitor of HDAC enzyme, can restore the transcriptional activity of ERalpha inhibited by HBx. Our data suggest that HBx and ERDelta5 may play a negative role in ERalpha signaling and that ERalpha agonists may be developed for HCC therapy.
###end p 2
###begin title 3
INTRODUCTION
###end title 3
###begin p 4
###xml 143 144 143 144 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b1">1</xref>
###xml 286 287 286 287 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b2">2</xref>
###xml 701 702 701 702 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b3">3</xref>
###xml 727 728 727 728 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b4">4</xref>
###xml 776 777 776 777 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b5">5</xref>
###xml 809 810 809 810 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b6">6</xref>
###xml 870 871 870 871 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b7">7</xref>
###xml 906 907 906 907 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b8">8</xref>
###xml 1125 1126 1121 1122 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b9">9</xref>
###xml 1127 1129 1123 1125 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b12">12</xref>
###xml 25 42 <span type="species:ncbi:10407">Hepatitis B virus</span>
###xml 44 47 <span type="species:ncbi:10407?0.9699783742526397">HBV</span>
###xml 260 263 <span type="species:ncbi:10407?0.9699783742526397">HBV</span>
###xml 384 399 <span type="species:ncbi:10090">transgenic mice</span>
Prolonged infection with Hepatitis B virus (HBV) has been clearly recognized as a major etiological factor for hepatocellular carcinoma (HCC) (1). HBx, a virally encoded protein of 154 amino acids, has been shown to have multifunctional activities relevant to HBV-mediated oncogenesis (2). HBx is involved in neoplastic transformation in cultured cells and can induce liver cancer in transgenic mice. Although HBx does not bind to double-stranded DNA, it regulates transcription of a variety of cellular and viral genes by interacting with cellular proteins and/or components of signal transduction pathways. HBx has been shown to interact with transcriptional factors such as RPB5 of RNA polymerase (3), TATA-binding protein (4), basic region/leucine zipper (bZIP) proteins (5) and the tumor suppressor p53 (6). Besides, it can also associate with serine protease TL2 (7) and cellular DNA repair protein (8). The interaction of HBx with these proteins leads to activation of signal transduction pathways including the Ras/Raf/mitogen-activated protein kinase, protein kinase C, Jak1-STAT and nuclear factor kappaB pathways (9-12). However, the intracellular signaling pathways in which Hbx is involved are not fully elucidated.
###end p 4
###begin p 5
###xml 115 117 115 117 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b13">13</xref>
###xml 254 256 254 256 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b14">14</xref>
###xml 257 259 257 259 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b17">17</xref>
###xml 381 383 367 369 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b18">18</xref>
###xml 384 386 370 372 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b21">21</xref>
###xml 31 34 <span type="species:ncbi:10407?0.9699783742526397">HBV</span>
###xml 63 67 <span type="species:ncbi:10090">mice</span>
###xml 86 89 <span type="species:ncbi:10407?0.9699783742526397">HBV</span>
###xml 159 162 <span type="species:ncbi:9606">men</span>
###xml 171 176 <span type="species:ncbi:9606">women</span>
Estrogen was shown to suppress HBV replication in male athymic mice transplanted with HBV-transfected HepG2 cells (13). The fact that HCC is more prevalent in men than in women suggests that estrogen may play an important role in the development of HCC (14-17). Estrogen exerts its function through its two nuclear receptors, estrogen receptor alpha and beta (ERalpha and ERbeta) (18-21). ERalpha and ERbeta share structural similarity characterized by several functional domains. Two distinct activation function (AF) domains, AF-1 and AF-2, located at the N-terminus and the C-terminus, respectively, contribute to the transcriptional activity of the two receptors. The DNA-binding domain (DBD) of the two receptors is well conserved and centrally located. Activation of ERs is responsible for many biological processes, including cell growth, differentiation and apoptosis.
###end p 5
###begin p 6
###xml 52 54 48 50 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b22">22</xref>
###xml 192 194 184 186 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b23">23</xref>
###xml 195 197 187 189 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b24">24</xref>
###xml 363 365 351 353 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b25">25</xref>
###xml 493 495 477 479 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b26">26</xref>
###xml 496 498 480 482 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b28">28</xref>
###xml 39 44 <span type="species:ncbi:9606">human</span>
###xml 123 131 <span type="species:ncbi:9606">patients</span>
###xml 302 310 <span type="species:ncbi:9606">patients</span>
###xml 334 342 <span type="species:ncbi:9606">patients</span>
###xml 731 734 <span type="species:ncbi:9606">men</span>
ERalpha has been well characterized in human liver (22). ERalpha is expressed in the liver of both healthy individuals and patients with HCC, with no differences in the pattern of expression (23,24). In contrast, the mutant form with the entire exon 5 deleted (ERDelta5) is preferentially expressed in patients with HCC compared with patients with normal livers (25). The presence of the liver ERDelta5 transcript in the tumor was the strongest negative predictor of survival in operable HCC (26-28). Its presence also correlates with a higher clinical aggressiveness of the tumor in comparison with tumors characterized by wild-type ERalpha (wt ERalpha) transcript. High rates of ERDelta5 expression have been shown to present in men at high-risk for HCC development. ERDelta5 encodes the hormone-independent AF-1 domain, as well as the DBD. Although ERDelta5 was demonstrated to be coexpressed with wt ERalpha in HCC, the role of ERDelta5 in ERalpha signaling remains to be investigated.
###end p 6
###begin p 7
###xml 16 23 16 23 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 28 36 28 36 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 456 464 428 436 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 469 476 441 448 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
On the basis of in vivo and in vitro functional relevance of the estrogen/ERalpha axis and HBx in the development of HCC, we hypothesized that HBx may play a role in ERalpha signaling. Here, we show that ERDelta5 has a dominant negative activity in hepatoma cells when expressed together with wt ERalpha. HBx decreases ERalpha transcriptional activity, and HBx and ERDelta5 have additive effect on inhibition of ERalpha transactivation. We further present in vitro and in vivo evidence that both HBx and ERDelta5 interact with ERalpha. HBx inhibits ERalpha signaling possibly through recruitment of histone deacetylase 1 (HDAC1).
###end p 7
###begin title 8
MATERIALS AND METHODS
###end title 8
###begin title 9
Plasmids
###end title 9
###begin p 10
###xml 33 35 33 35 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b29">29</xref>
###xml 46 48 46 48 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b30">30</xref>
###xml 49 51 49 51 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b31">31</xref>
###xml 63 65 63 65 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b32">32</xref>
###xml 88 90 84 86 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b33">33</xref>
###xml 275 277 267 269 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b34">34</xref>
###xml 210 215 <span type="species:ncbi:9606">human</span>
###xml 1193 1198 <span type="species:ncbi:9606">human</span>
The reporter constructs ERE-Luc (29), C3-LUC (30,31), pS2-LUC (32) and pS2DeltaERE-LUC (33), and expression vector for ERalpha have been described previously. For the generation of FLAG-tagged full-length HBx, human HBx DNA was amplified by PCR using pHBV3091 as a template (34). The amplified HBx DNA was cloned into pcDNA3 vector harboring FLAG epitope sequence (pcDNA3-FLAG). The deletion mutant of HBx (Delta73-120) was constructed by inserting the recombinant PCR-generated fragment from the HBx DNA into the pcDNA3-FLAG vector. The expression vectors for the full-length ERalpha (1-595), ERalpha AF1 (1-185), ERalpha DBD (180-282), ERalpha AF2 (282-595), ERalpha AF2 (302-595) and ERDelta5 (370 amino acids with a novel five-amino acid residue COOH terminus) were made by introducing the corresponding cDNAs into pcDNA3 (Invitrogen). Enhanced green fluorescent protein (EGFP)-tagged HBx construct was generated by inserting HBx DNA into pEGFP-C1 (Clontech), and red fluorescent protein (RFP)-tagged ERalpha construct by inserting ERalpha cDNA into pDsRed-N1 (Clontech). A cDNA fragment encoding entire coding region of HDAC1 was obtained by RT-PCR using as a template total RNA from the human hepatoma cell line HepG2, and the cDNA fragment was inserted in frame into a pcDNA3 vector linked with HA tag at the amino terminus. Plasmids encoding GST-fusion proteins were prepared by amplification of each sequence by standard PCR methods, and the resulting fragments were cloned in frame into pGEX-KG (Amersham Pharmacia Biotech) using appropriate restriction sites. All of the constructs were confirmed by sequencing. Details of cloning are available upon request.
###end p 10
###begin title 11
Transfection and luciferase assay
###end title 11
###begin p 12
###xml 686 687 660 661 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 894 896 865 867 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b35">35</xref>
###xml 96 102 <span type="species:ncbi:9913">bovine</span>
HepG2 and SMMC-7721 cells were routinely grown in DMEM (Invitrogen) supplemented with 10% fetal bovine serum (FBS). For transfection, cells were seeded in 12-well plates containing phenol red-free DMEM medium supplemented with 10% charcoal-stripped FBS (Hyclone). The cells were transfected using Lipofectamine 2000 (Invitrogen) with 0.2 microg of ERE-LUC, C3-LUC, pS2-LUC or pS2DeltaERE-LUC reporter plasmid, 50 ng of ERalpha expression plasmid, 250 ng to 2 microg of the expression vector for HBx and 0.1 microg of beta-galactosidase reporter as an internal control. The empty vector pcDNA3 was used to adjust the total amount of DNA. After treatment with 10 nM of 17beta-estradiol (E2) and 100 nM 4-hydroxytamoxifen (4-OHT) for 24 h, or 100 nM trichostatin A (TSA) for 12 h, the cells were harvested, and luciferase and beta-galactosidase activities were determined as described previously (35). All experiments were repeated at least five times.
###end p 12
###begin title 13
GST pull-down assay
###end title 13
###begin p 14
###xml 46 52 46 52 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E.coli</italic>
###xml 139 141 129 131 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b36">36</xref>
###xml 414 422 396 404 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 486 488 468 470 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">35</sup>
###xml 498 506 480 488 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 46 52 <span type="species:ncbi:110766|species:ncbi:562">E.coli</span>
GST and GST-fusion proteins were expressed in E.coli DH5alpha, with the induction of protein expression performed at 20degreesC overnight (36). After large-scale preparation, purification of the recombinant proteins were performed according to the manufacturer's instruction (Pharmacia) using glutathione-Sepharose beads. The expression plasmid for the ERalpha, ERalpha deletion mutants, HBx or HDAC1 was used for in vitro transcription and translation in the TNT System (Promega). The 35S-labeled in vitro translated products were incubated with approximately10 microg of GST derivatives bound to glutathione-Sepharose beads in 500 microl binding buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1 mM EDTA, 0.3 mM DTT, 0.1% NP-40 and protease inhibitor tablets from Roche) at 4degreesC. The beads were precipitated, washed four times with binding buffer, eluted in SDS-PAGE sample buffer, and analyzed by SDS-PAGE. After electrophoresis, the gel was dried and exposed to X-ray films.
###end p 14
###begin title 15
Coimmunoprecipitation
###end title 15
###begin p 16
HepG2 cells were transfected with the indicated plasmids using Lipofectamine 2000 (Invitrogen), washed with phosphate-buffered saline (PBS), lysed in 0.5 ml lysis buffer (50 mM Tris, pH 8.0, 250 mM NaCl, 0.25% NP-40, 1 mM DTT and protease inhibitor tablets from Roche), and immunoprecipitated with anti-FLAG-agarose beads (Sigma) for 3 h at 4degreesC. The beads were centrifuged, washed four times with the lysis buffer, and eluted in 30 microl of SDS-PAGE sample buffer. The eluted proteins were separated by SDS-PAGE, followed by immunoblotting with anti-ERalpha (Santa Cruz Biotech), anti-HA (Sigma) or anti-FLAG (Sigma) according to the standard procedures.
###end p 16
###begin p 17
For reimmunoprecipitation, the immune complexes precipitated with anti-FLAG were eluted under native condition by a competition with 3x FLAG peptide according to the manufacturer's instructions (Sigma). The eluate was precleared with 20 microl of 50% protein A agarose beads (Santa Cruz Biotech) for 30 min. Proteins were reprecipitated with anti-ERalpha or control serum (Santa Cruz Biotech) plus 20 microl of protein A agarose beads. Reprecipitates were washed four times with lysis buffer, eluted by boiling in SDS-PAGE sample buffer, and resolved by SDS-PAGE, followed by immunoblotting.
###end p 17
###begin p 18
###xml 79 82 <span type="species:ncbi:10407?0.9699783742526397">HBV</span>
###xml 92 99 <span type="species:ncbi:9606">patient</span>
For detecting interaction of endogenous HBx with ERalpha, liver tissue from an HBV positive patient (General Hospital of PLA, Beijing) was lysed in 1.0 ml RIPA buffer (PBS, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS and protease inhibitor tablets from Roche), and immunoprecipitated with anti-ERalpha or control serum (Santa Cruz). After extensive washing with RIPA buffer, the immunoprecipitates were resolved by SDS-PAGE, followed by western blot analysis using anti-HBx (Chemicon).
###end p 18
###begin title 19
Confocal microscopy
###end title 19
###begin p 20
###xml 341 342 338 339 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
HepG2 cells were seeded in 6-well dishes with glass coverslips containing phenol red-free DMEM medium (Invitrogen) supplemented with 10% charcoal-stripped FBS (Hyclone). Cells were transiently transfected with the indicated plasmids using lipofectamine 2000. Six hours after transfection, cells were treated with 10 nM of 17beta-estradiol (E2) for various times. Nuclear DNA was visualized with 4',6'-diamidino-2-phenylindole (DAPI). The subcellular localization of EGFP-HBx and RFP-ERalpha was analyzed with a Radiance 2100 confocal microscope (Bio-Rad). Fluorescence was detected with appropriate filter sets (the green signal, excitation 488 nm, dichroic mirror 560 DCLPXR, emission HQ 515/30; the red signal, excitation 543 nm, dichroic mirror 650 DCLPXR, emission HQ590/70).
###end p 20
###begin title 21
RESULTS
###end title 21
###begin title 22
Repression of ERalpha transcriptional activity by ERDelta5
###end title 22
###begin p 23
###xml 64 65 60 61 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 149 151 141 143 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b37">37</xref>
###xml 382 390 366 374 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Figure 1</xref>
###xml 412 413 396 397 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 114 119 <span type="species:ncbi:9606">human</span>
To examine the effects of wt ER and the ER variant ERDelta5 on E2-responsive gene transcription, ERalpha-negative human liver carcinoma HepG2 cells (37) were transiently transfected with wt ERalpha and/or ERDelta5, along with the synthetic estrogen-responsive reporter plasmid ERE-LUC, or the natural estrogen-responsive reporters pS2-Luc and Complement 3-Luc (C3-Luc). As shown in Figure 1, in the presence of E2, ERalpha stimulated the transcription of these reporter genes, whereas ERDelta5 had little effect. Importantly, when wt ER and ERDelta5 were co-transfected into the HepG2 cells in equal amounts, ERDelta5 was able to reduce the transcriptional activity of wt ER. These data suggest that ERDelta5 is able to interfere with the transcriptional activity of wt ER and to act as a dominant negative receptor.
###end p 23
###begin title 24
###xml 37 45 29 37 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 50 57 42 49 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
Interaction of ERalpha with ERDelta5 in vitro and in vivo
###end title 24
###begin p 25
###xml 249 257 237 245 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 269 271 257 259 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">35</sup>
###xml 364 373 344 353 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Figure 1B</xref>
###xml 412 413 392 393 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 524 529 488 493 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vitro</italic>
The dominant negative property of the ER variant ERDelta5 could involve the formation of a heterodimer between ERDelta5 and wt ERalpha through protein-protein interactions. To test this possibility, GST pull-down experiments were performed in which in vitro translated 35S-methionine-labeled ERDelta5 was incubated with full-length GST-ERalpha or GST. As shown in Figure 1B, in both the absence and presence of E2, ERDelta5 bound to GST-ERalpha, but not to GST, suggesting that ERalpha physically interacts with ERDelta5 in vitro.
###end p 25
###begin p 26
###xml 54 61 46 53 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 184 185 168 169 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 406 415 378 387 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Figure 1C</xref>
To determine whether ERDelta5 interacted with ERalpha in vivo, HepG2 cells were transfected with ERalpha and FLAG-tagged ERDelta5, and grown both in the absence and presence of 10 nM E2. The cells were then subjected to immunoprecipitation (IP) with FLAG antibody-conjugated agarose beads, followed by immunoblot (IB) with ERalpha antibody, which recognizes both ERalpha and ERDelta5 proteins. As shown in Figure 1C, ERalpha could be co-immunoprecipitated in a ligand-independent manner in the presence, but not in the absence, of FLAG- ERDelta5. These results suggest that ERDelta5 interacts with ERalpha in hepatoma cells.
###end p 26
###begin title 27
Repression of ERalpha transcriptional activity by HBx
###end title 27
###begin p 28
###xml 300 309 292 301 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig2">Figure 2A</xref>
###xml 805 814 785 794 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig2">Figure 2B</xref>
To gain insight into the functional role of HBx in HCC, the effect of HBx protein on ERalpha transactivation function was investigated. HepG2 cells were co-transfected with the synthetic estrogen response element (ERE)-containing reporter ERE-LUC, ERalpha, and increasing amounts of HBx. As shown in Figure 2A, as little as 250 ng of HBx was sufficient to exert a potent repression of ERalpha transactivation function and the extent of repression increased with increasing amount of HBx expression, suggesting that HBx decreased ERalpha transcriptional activity in a dose-dependent manner. Similar repression was observed in other liver cancer cells such as SMMC-7721 (data not shown). It should be noted that the decreased transcriptional activity was not a result of reduced ERalpha protein production (Figure 2B).
###end p 28
###begin p 29
###xml 234 249 230 245 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig2">Figure 2C and D</xref>
###xml 536 537 524 525 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 593 602 581 590 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig2">Figure 2E</xref>
###xml 860 862 844 846 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b38">38</xref>
###xml 1039 1042 1020 1023 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cis</italic>
###xml 1048 1053 1029 1034 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">trans</italic>
To test the effect of HBx on natural estrogen-responsive promoter activity, HepG2 cells were co-transfected with the natural ERE-containing reporter C3-Luc or pS2-Luc, together with expression vectors for ERalpha and HBx. As shown in Figure 2C and D, activation of the C3 promoter by ERalpha was not affected by HBx, whereas activation of the pS2 promoter by ERalpha was significantly repressed by HBx, indicating that the effect of HBx is promoter specific. Interestingly, mutations of the EREs at the pS2 promoter abolished both the E2-dependent gene activation and HBx-mediated repression (Figure 2E). A similar repressive effect of HBx on ERalpha-mediated transcription was also observed in SMMC-7721 cells (data not shown). As another control of the effects of HBx on transcription, HBx stimulated Smad-mediated gene transcription as reported previously (38), when HepG2 cells were co-transfected with the synthetic TGFbeta-responsive transcriptional reporter p3TP-Lux (data not shown). Taken together, our data suggest that specific cis- and trans-acting elements are required for the HBx-mediated repression.
###end p 29
###begin title 30
Additive repression of specific ERalpha responsive gene transcription by HBx and ERDelta5
###end title 30
###begin p 31
###xml 561 572 525 536 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig3">Figure 3A&#8211;D</xref>
Since both HBx and ERDelta5 repressed ERalpha transcriptional activity, we determined if HBx and ERDelta5 had synergistic or additive effect on ERalpha transactivation. We co-transfected HepG2 cells with the ERE-Luc, C3-Luc, pS2-Luc or pS2DeltaERE-Luc reporter construct, together with HBx or ERDelta5 or in combination. As expected, HBx alone inhibited the transcription of the ERE-Luc and pS2-LUC reporter genes but not the C3-Luc and pS2DeltaERE-Luc reporter genes. ERDelta5 alone repressed the transcription of all of reporter genes except pS2DeltaERE-Luc (Figure 3A-D). Cotransfection with HBx plus ERDelta5 expression vectors gave an additive effect in repressing the transcription of the pS2-LUC reporter gene but not the other reporter genes. These results indicate that the additive effect of HBx and ERDelta5 on ERalpha-responsive gene transcription is promoter specific.
###end p 31
###begin p 32
###xml 262 271 246 255 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig3">Figure 3E</xref>
###xml 401 402 378 379 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 425 426 402 403 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
To examine the effect of antiestrogen on suppression of ERalpha transactivation by HBx and ERDelta5, HepG2 cells were co-transfected with the pS2-Luc reporter, ERalpha, and HBx or ERDelta5 or in combination, and subsequently treated with the antiestrogen 4-OHT (Figure 3E). 4-OHT alone did not have significant effect on HBx- or ERDelta5-mediated repression, whereas combination of 17beta-estradiol (E2) and 4-OHT inhibited E2-induced ERalpha transactivation regardless of HBx and ERDelta5.
###end p 32
###begin title 33
###xml 32 40 28 36 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 45 52 41 48 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
Interaction of HBx with ERalpha in vitro and in vivo
###end title 33
###begin p 34
###xml 112 113 112 113 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b3">3</xref>
###xml 114 115 114 115 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b6">6</xref>
###xml 356 358 348 350 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">35</sup>
###xml 432 441 420 429 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig4">Figure 4A</xref>
###xml 491 493 479 481 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">35</sup>
###xml 534 542 518 526 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
HBx has been shown to regulate viral and cellular gene transcription by interacting with transcription factors (3-6). Our observation that HBx could function as a co-repressor to repress ERalpha transactivation raised the possibility that HBx might physically interact with ERalpha. To test this possibility, GST pull-down experiments were performed using 35S-labeled full-length ERalpha and GST-tagged full-length HBx. As shown in Figure 4A, GST-HBx, but not GST, was able to pull down the 35S-labeled ERalpha, thus demonstrating an in vitro interaction between HBx and ERalpha.
###end p 34
###begin p 35
###xml 168 177 160 169 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig4">Figure 4B</xref>
###xml 648 657 620 629 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig4">Figure 4C</xref>
###xml 794 803 766 775 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig4">Figure 4C</xref>
###xml 901 908 869 876 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 457 460 <span type="species:ncbi:10407?0.9699783742526397">HBV</span>
###xml 470 477 <span type="species:ncbi:9606">patient</span>
###xml 703 709 <span type="species:ncbi:9986">rabbit</span>
To test if HBx binds to ERalpha in mammalian cells, HepG2 cells were transfected with ERalpha and FLAG-tagged HBx, and harvested for coimmunoprecipitation experiments. Figure 4B demonstrates that ERalpha could be co-immunoprecipitated in a ligand-independent manner in the presence of FLAG-HBx but not FLAG-tagged empty vector. To ascertain the HBx-ERalpha interaction in a more physiological context, the endogenous ERalpha protein from liver tissue of an HBV positive patient was immunoprecipitated with an anti-ERalpha antibody. Subsequent immunoblotting with anti-HBx antibody indicated that the endogenous HBx was coprecipitated with ERalpha (Figure 4C). In the negative control experiment, normal rabbit serum or an irrelevant antibody, anti-FLAG antibody, did not immunoprecipitate HBx (Figure 4C and data not shown). Taken together, these data strongly suggest that HBx interacts with ERalpha in vivo.
###end p 35
###begin p 36
###xml 76 85 68 77 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig3">Figure 3C</xref>
###xml 316 325 292 301 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig4">Figure 4D</xref>
###xml 464 473 432 441 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig3">Figure 3C</xref>
###xml 543 552 503 512 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig4">Figure 4D</xref>
Since HBx and ERDelta5 have additive effect on the ERalpha transactivation (Figure 3C), the effect of ERDelta5 on the HBx-ERalpha interaction was investigated. HepG2 cells were transfected with FLAG-tagged HBx, ERalpha, and increasing amounts of ERDelta5, and collected for coimmunoprecipitation assays. As shown in Figure 4D, Both ERalpha and ERDelta5 were coprecipitated with FLAG-tagged HBx, but not FLAG control vector. Consistent with the functional results (Figure 3C), ERDelta5 had little effect on the interaction of ERalpha with HBx (Figure 4D).
###end p 36
###begin title 37
Co-localization of ERalpha with HBx
###end title 37
###begin p 38
###xml 67 74 63 70 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in situ</italic>
###xml 555 557 539 541 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b39">39</xref>
###xml 560 569 544 553 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig4">Figure 4E</xref>
###xml 682 691 662 671 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig4">Figure 4E</xref>
###xml 964 973 936 945 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig4">Figure 4E</xref>
To confirm the protein-protein interaction between HBx and ERalpha in situ, constructs were made for EGFP-tagged HBx (EGFP-HBx) and RFP-tagged ERalpha. Based on their ability to regulate the ERE-Luc reporter activity, these fluorescent protein-tagged constructs were similar to those with or without the above mentioned FLAG tag (data not shown). HepG2 cells were then co-transfected with EGFP-HBx and RFP-ERalpha, and analyzed for co-localization of ERalpha with HBx. As expected, EGFP-HBx localizes in both the cytoplasm and the nucleus of HepG2 cells (39) (Figure 4E). RFP-ERalpha localizes essentially in the nucleus of HepG2 cells in both the presence and absence of estrogen (Figure 4E and data not shown). Co-localization studies indicated that EGFP-HBx colocalized with RFP-ERalpha, but not with the empty vector RFP, predominantly in the cell nucleus in a ligand-independent manner, suggesting that ERalpha may facilitate the nuclear localization of HBx (Figure 4E and data not shown).
###end p 38
###begin title 39
Mapping of the ERalpha and HBx interaction regions
###end title 39
###begin p 40
###xml 173 175 169 171 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">35</sup>
###xml 196 204 192 200 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 276 285 268 277 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig4">Figure 4F</xref>
To define the interacting region(s) of HBx on ERalpha, GST-fusion proteins containing various regions of HBx were prepared and the ability of each of these to interact with 35S-methionine-labeled in vitro translated full-length ERalpha were determined by GST pull-down assay (Figure 4F). Deletion of only the first 51 or last 11 amino acids of HBx did not affect the ability to interact with ERalpha. The GST-HBx(73-120) containing part of the transactivation domain bound specifically to ERalpha, but the GST-HBx(1-72) and the GST-HBx(121-154) did not.
###end p 40
###begin p 41
###xml 79 81 75 77 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">35</sup>
###xml 102 110 98 106 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 178 187 170 179 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig4">Figure 4G</xref>
To map the domain of ERalpha responsible for interaction with HBx, a series of 35S-methionine-labeled in vitro translated ERalpha mutants were used in GST pull-down experiments (Figure 4G). The ERalpha(282-595) and the ERalpha(302-595) containing the AF2 domain were found to associate with HBx, whereas the ERalpha(1-185) containing the AF1 and the ERalpha(180-282) containing the DBD did not. ERDelta5, which has amino acid residues 1-365 of ERalpha also interacted with HBx, although with weak binding affinity.
###end p 41
###begin title 42
Interaction of HBx with ERalpha is required for inhibition of ERalpha transactivation function
###end title 42
###begin p 43
###xml 395 404 375 384 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig5">Figure 5A</xref>
###xml 604 613 572 581 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig5">Figure 5B</xref>
###xml 822 831 774 783 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig5">Figure 5C</xref>
To test the possibility that the interaction of HBx with ERalpha is required for the repression of ERalpha transactivation function, the HBx mutant [HBx(Delta73-120)] in which the interaction region from amino acids 73 to 120 of HBx was deleted was constructed. HepG2 cells were co-transfected with the ERE-LUC reporter, ERalpha, and FLAG-tagged full-length HBx or HBx(Delta73-120). As shown in Figure 5A, the mutation lacking the ERalpha-binding site abrogated the repression of ERalpha transactivation function by HBx. Notably, FLAG-tagged HBx and HBx(Delta73-120) were expressed at comparable levels (Figure 5B). To determine if HBx(Delta73-120) did lose the ability to interact with ERalpha in HepG2 cells, coimmunoprecipitation experiments were performed. As expected, HBx(Delta73-120) did not interact with ERalpha (Figure 5C). Taken together, these findings suggest that interaction of HBx with ERalpha is required for repression of ERalpha transactivation function.
###end p 43
###begin title 44
HBx, ERalpha and HDAC1 form a complex
###end title 44
###begin p 45
###xml 232 241 228 237 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig6">Figure 6A</xref>
###xml 243 251 239 247 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 360 368 356 364 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
To investigate whether the observed repression of ERalpha-responsive gene transcription by HBx was associated with recruitment of HDAC complexes, we examined the interaction between HBx and HDAC1 by GST pull-down assay. As shown in Figure 6A, in vitro translated HDAC1 interacted with GST-HBx, but not with GST alone, indicating that HBx associated with HDAC1 in vitro.
###end p 45
###begin p 46
###xml 64 71 64 71 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 128 137 128 137 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig6">Figure 6B</xref>
###xml 330 337 330 337 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
To determine whether the interaction of HBx with HDAC1 occurred in vivo, we performed coimmunoprecipitation and immunoblotting (Figure 6B). Transient expression of FLAG-tagged HBx, but not control FLAG vector, in HepG2 cells was accompanied by interaction with HA-tagged HDAC1. These results suggest that HBx interacts with HDAC1 in vivo.
###end p 46
###begin p 47
###xml 308 317 296 305 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig6">Figure 6C</xref>
###xml 844 853 816 825 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig6">Figure 6D</xref>
###xml 1053 1060 1021 1028 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
To examine whether HBx, ERalpha and HDAC1 formed a complex, HepG2 cells were transfected with ERalpha and HA-tagged HDAC1 with or without FLAG-tagged HBx. The cells were then subjected to immunoprecipitation with FLAG antibody-conjugated agarose beads, followed by immunoblot with ERalpha and HA antibodies (Figure 6C). Both ERalpha and HDAC1 were coprecipitated with FLAG-tagged HBx, but not FLAG control vector. To further confirm the possibility of a ternary complex among HBx, ERalpha, and HDAC1, the immune complexes precipitated with FLAG antibody were eluted with a FLAG peptide, and subjected to a second immunoprecipitation with an anti-ERalpha antibody. The anti-ERalpha immunoprecipitates were then subjected to immunoblotting with anti-HA to detect HA-tagged HDAC1. HA-tagged HDAC1 was present after sequential immunoprecipitation (Figure 6D). In contrast, HA-tagged HDAC1 was absent after a second immunoprecipitation with control antibody. These data provide strong evidence that HBx, ERalpha and HDAC1 together can form a ternary complex in vivo.
###end p 47
###begin title 48
HDAC inhibitor relieves repression of ERalpha transactivation function by HBx
###end title 48
###begin p 49
###xml 286 294 282 290 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig7">Figure 7</xref>
###xml 446 447 438 439 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
Our observation that HBx interacts with HDAC1 raises the possibility that the repression of ERalpha functions by HBx could be HDAC dependent. To this end, we examined the effect of TSA, a specific inhibitor of HDAC enzyme, on HBx-induced repression of ERE transcription in HepG2 cells (Figure 7). We found that HBx-mediated repression of ERalpha transcriptional activity could be effectively relieved by inhibiting HDAC activity. Interestingly, E2 and TSA have additive or synergistic effect in stimulating ERalpha transcriptional activity. These data suggest that HBx may recruit HDAC enzyme to repress ERE-mediated transcription.
###end p 49
###begin title 50
DISCUSSION
###end title 50
###begin p 51
###xml 132 137 <span type="species:ncbi:9606">human</span>
In the present study, we demonstrated for the first time that both ERDelta5 and HBx can inhibit ERalpha transcriptional activity in human liver cancer cells. We found that the repression of ERalpha transactivation function by ERDelta5 and HBx is mediated by their physical interaction with ERalpha. The binding of HBx with ERalpha is important for HBx-induced repression of ERalpha transactivation function because the HBx deletion mutant that lacks ERalpha-binding site completely abolished the repression of ERalpha transcriptional activity by HBx. Furthermore, we have shown that ERDelta5 and HBx have additive but not synergistic effect on repression of ERalpha-responsive gene transcription, suggesting that ERDelta5, ERalpha and HBx may not form a complex.
###end p 51
###begin p 52
###xml 134 136 134 136 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b40">40</xref>
###xml 137 139 137 139 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b41">41</xref>
###xml 287 289 287 289 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b13">13</xref>
###xml 632 634 620 622 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b25">25</xref>
###xml 635 637 623 625 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b28">28</xref>
###xml 894 895 866 867 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1092 1094 1056 1058 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b42">42</xref>
###xml 1390 1391 1342 1343 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1551 1553 1495 1497 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b43">43</xref>
###xml 1554 1556 1498 1500 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b44">44</xref>
###xml 60 65 <span type="species:ncbi:9606">human</span>
###xml 211 214 <span type="species:ncbi:10407?0.9699783742526397">HBV</span>
###xml 524 532 <span type="species:ncbi:9606">patients</span>
###xml 808 813 <span type="species:ncbi:9606">human</span>
###xml 1065 1070 <span type="species:ncbi:9606">human</span>
###xml 1173 1178 <span type="species:ncbi:9606">human</span>
###xml 1481 1486 <span type="species:ncbi:9606">human</span>
###xml 1510 1515 <span type="species:ncbi:9606">human</span>
Estrogen has been reported to promote the growth of certain human neoplasms, notably tumors of the breast, endometrium and pituitary (40,41). In sharp contrast, Estrogen was shown to suppress the replication of HBV that has been clearly recognized as a major etiological factor for HCC (13). Studies of chemical carcinogenesis also suggested that ERalpha may modulate HCC risk by inhibiting the malignant transformation of pre-neoplastic liver cells. The ERalpha variant ERDelta5 was shown to be preferentially expressed in patients with HCC compared with parents with normal livers and to be associated with poor clinical outcome (25-28). Therefore, it is important to determine whether the ERDelta5 is able to interfere with the transcriptional activity of wt ERalpha. When ERDelta5 was expressed alone in human ERalpha-negative hepatoma HepG2 cells, it had little effect on either basal or E2-mediated ERE-containing reporter activity. However, when ERDelta5 was coexpressed with wt ERalpha, the reporter activity was significantly decreased, similar to that in human breast cancer cells (42). Our data suggest that ERDelta5 functions as a dominant negative receptor in human liver cancer cells. Although both in breast and liver cancer cells, ERDelta5 displays dominant negative activity, ERDelta5 was found to act as a dominant positive receptor isoform and facilitate both basal and E2-stimulated ERE-mediated transcription of wt ERalpha when coexpressed in ERalpha-negative human osteosarcoma U2-OS and human endometrial cancer Ishikawa cells (43,44). These discordant results could be due to the different cell types used, suggesting that some factors required for ERalpha transcriptional activity may be tissue specific.
###end p 52
###begin p 53
###xml 104 105 104 105 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b3">3</xref>
###xml 106 107 106 107 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b5">5</xref>
###xml 108 110 108 110 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b45">45</xref>
###xml 299 301 299 301 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b46">46</xref>
###xml 557 559 545 547 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b47">47</xref>
###xml 560 562 548 550 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b48">48</xref>
###xml 952 954 934 936 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b49">49</xref>
###xml 1187 1188 1169 1170 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b6">6</xref>
###xml 1378 1380 1348 1350 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b50">50</xref>
###xml 1676 1678 1638 1640 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b51">51</xref>
###xml 1818 1819 1776 1777 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1994 1995 1944 1945 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 2249 2251 2191 2193 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b52">52</xref>
A number of studies have shown that HBx interacts with proteins involved in transcriptional regulation (3-5,45). Most of the studies identify HBx as a co-activator of transcription. For example, HBx enhances the transcription efficacy of the CREB transcription factor through interaction with CREB (46). HBx associates with hypoxia inducible factor-1alpha (HIF-1alpha), a major transcriptional factor that regulates expression of angiogenic factors such as vascular endothelial growth factor (VEGF), and enhances the transactivation function of HIF-1alpha (47,48). HBx was also shown to stimulate transcription by activating cellular signal transduction pathways. For instance, HBx is involved in activating Wnt/beta-catenin signaling by stabilizing cytoplasmic beta-catenin. HBx can stimulate activator protein 1 (AP-1) via two distinct pathways, the Ras-Raf-mitogen-activated protein kinase (MAPK) and the c-Jun amino-terminal kinase (JNK) cascades (49). On the other hand, HBx was found to act as a co-repressor of transcription. HBx interferes with p53 by direct binding and by sequestering p53 in the cytoplasm, resulting in the abrogation of p53-mediated transcriptional activity (6). HBx binds to DBD of peroxisome proliferator-activated receptor gamma (PPARgamma), a member of the steroid hormone receptor superfamily, and suppresses PPARgamma-mediated transactivation (50). Our results showed that HBx represses ERalpha transcriptional activity through interaction with ERalpha and recruitment of HDAC1, which belongs to a class of enzymes involved in deacetylation of hyperacetylated histone tails, leading to compaction of chromatin and transcriptional repression (51). Importantly, the inhibitory effect of HBx on ERalpha transcriptional activity was antagonized by the HDAC inhibitor TSA. Interestingly, E2 and TSA are additive or synergistic in inducing ERalpha transcriptional activity. The fact that HBx represses ERalpha transcriptional activity in the presence or absence of E2 suggests that HBx regulates ERalpha transcriptional activity in a ligand-independent manner. Recently, the tumor suppressor BRCA1 has been shown to mediate ligand-independent transcriptional repression of ERalpha in a manner dependent on HDAC activity (52). Our observation that HBx, ERalpha and HDAC1 can form a complex and TSA can effectively reverse ligand-independent repression mediated by HBx suggests that one of the underlying mechanisms by which HBx mediates ligand-independent repression of ERalpha transcriptional activity may involve targeted recruitment by unliganded, promoter-bound ERalpha of a HBx-associated HDAC activity.
###end p 53
###begin p 54
###xml 115 117 115 117 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b37">37</xref>
###xml 366 368 366 368 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b53">53</xref>
###xml 454 456 454 456 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b54">54</xref>
###xml 457 459 457 459 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b56">56</xref>
###xml 1232 1234 1232 1234 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b37">37</xref>
###xml 247 255 <span type="species:ncbi:9606">patients</span>
###xml 356 364 <span type="species:ncbi:9606">patients</span>
###xml 501 509 <span type="species:ncbi:9606">patients</span>
###xml 803 811 <span type="species:ncbi:9606">patients</span>
###xml 884 892 <span type="species:ncbi:9606">patients</span>
Tamoxifen is considered to be relatively more estrogenic than antiestrogenic in the urine, bone and liver tissues (37). Thus, tamoxifen has been used for the treatment of liver cancer. Indeed, initial studies with a relatively small population of patients with HCC show regression of liver tumor mass and improved survival in some of the tamoxifen-treated patients (53). However, more and more recent controlled trials with this drug were disappointing (54-56). Tamoxifen does not prolong survival in patients with HCC and has an increasingly negative impact with increasing dose. There is also no appreciable advantage to quality of life with tamoxifen. These studies showed conclusively that, although the mechanisms by which tamoxifen negatively impacts HCC are not known, tamoxifen does not benefit patients with HCC and is likely to be detrimental. Thus, the use of tamoxifen in patients with HCC is not recommended. Our study indicated that 4-OHT, a metabolite of the tamoxifen with a more potent estrogen agonist/antagonist activity than tamoxifen, acts as a pure estrogen antagonist in HepG2 cells, which is in agreement with the previous study showing that tamoxifen functions as a pure estrogen antagonist in HepG2 cells (37). This may at least in part explain why tamoxifen is ineffective in the treatment of HCC.
###end p 54
###begin p 55
###xml 84 92 84 92 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 97 104 97 104 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 106 108 106 108 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b57">57</xref>
###xml 109 111 109 111 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b59">59</xref>
###xml 208 209 208 209 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b3">3</xref>
###xml 430 438 430 438 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 443 450 443 450 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 486 487 486 487 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 531 533 531 533 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b60">60</xref>
###xml 534 536 534 536 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b61">61</xref>
###xml 546 547 546 547 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
Recently, HDAC inhibitors have been used successfully to inhibit cancer cell growth in vitro and in vivo (57-59). TSA specifically inhibits classes I and II HDACs by binding directly to their catalytic site (3). Class I HDACs include HDAC1, HDAC2, HDAC3, HDAC8 and HDAC11, and Class II HDACs include HDACs 4-7 and HDACs 9-10. TSA regulates the expression of small subsets of growth-related genes and has potent antitumor activity in vitro and in vivo. In hepatoma cells, TSA induces a G2/M cell cycle arrest followed by apoptosis (60,61). Since E2 and TSA are additive or synergistic in inducing ERalpha transcriptional activity in hepatoma cells, it is important to develop more effective therapeutic agents for HCC that increase ERalpha transactivation function, with no obvious side effects.
###end p 55
###begin p 56
We thank Xuemin Zhang for technical assistance. This work was supported by the Key Technologies R&D Program (2002BA711A02-5) and National Natural Science Foundation (30571655, 30530320 and 30428012). Funding to pay the Open Access publication charges for this article was provided by the Key Technologies R&D Program.
###end p 56
###begin p 57
###xml 0 30 0 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Conflict of interest statement</italic>
Conflict of interest statement. None declared.
###end p 57
###begin title 58
REFERENCES
###end title 58
###begin article-title 59
###xml 0 17 <span type="species:ncbi:10407">Hepatitis B virus</span>
Hepatitis B virus infection
###end article-title 59
###begin article-title 60
###xml 0 17 <span type="species:ncbi:10407">Hepatitis B virus</span>
Hepatitis B virus X protein: a multifunctional viral regulator
###end article-title 60
###begin article-title 61
###xml 0 5 <span type="species:ncbi:9606">Human</span>
###xml 74 97 <span type="species:ncbi:10407">human hepatitis B virus</span>
Human RPB5, a subunit shared by eukaryotic nuclear RNA polymerases, binds human hepatitis B virus X protein and may play a role in X transactivation
###end article-title 61
###begin article-title 62
###xml 0 17 <span type="species:ncbi:10407">Hepatitis B virus</span>
Hepatitis B virus transactivator protein X interacts with the TATA-binding protein
###end article-title 62
###begin article-title 63
The hepatitis B pX protein promotes dimerization and DNA binding of cellular basic region/leucine zipper proteins by targeting the conserved basic region
###end article-title 63
###begin article-title 64
###xml 0 17 <span type="species:ncbi:10407">Hepatitis B virus</span>
Hepatitis B virus X protein inhibits p53 sequence-specific DNA binding, transcriptional activity, and association with transcription factor ERCC3
###end article-title 64
###begin article-title 65
###xml 15 32 <span type="species:ncbi:10407">hepatitis B virus</span>
Interaction of hepatitis B virus X protein with a serine protease, tryptase TL2 as an inhibitor
###end article-title 65
###begin article-title 66
###xml 0 17 <span type="species:ncbi:10407">Hepatitis B virus</span>
Hepatitis B virus X protein interacts with a probable cellular DNA repair protein
###end article-title 66
###begin article-title 67
###xml 10 13 <span type="species:ncbi:10407?0.9699783742526397">HBV</span>
###xml 15 18 <span type="species:ncbi:11103?0.9633797444211329|species:ncbi:11096?0.008773602899103566">HCV</span>
###xml 23 28 <span type="species:ncbi:54290?0.912621359223301">GBV-C</span>
###xml 29 32 <span type="species:ncbi:54290?0.993103448275862">HGV</span>
Impact of HBV, HCV and GBV-C/HGV on hepatocellular carcinomas in Europe: results of a European concerted action
###end article-title 67
###begin article-title 68
###xml 25 42 <span type="species:ncbi:10407">hepatitis B virus</span>
Increasing evidence that hepatitis B virus X gene protein and p53 protein may interact in the pathogenesis of hepatocellular carcinoma
###end article-title 68
###begin article-title 69
###xml 0 17 <span type="species:ncbi:10407">Hepatitis B virus</span>
Hepatitis B virus X protein: structure, function and biology
###end article-title 69
###begin article-title 70
###xml 0 17 <span type="species:ncbi:10407">Hepatitis B virus</span>
Hepatitis B virus X protein: searching for a role in hepatocarcinogenesis
###end article-title 70
###begin article-title 71
###xml 20 37 <span type="species:ncbi:10407">hepatitis B virus</span>
###xml 65 69 <span type="species:ncbi:10090">mice</span>
###xml 88 91 <span type="species:ncbi:10407?0.9699783742526397">HBV</span>
Estrogen suppresses hepatitis B virus expression in male athymic mice transplanted with HBV transfected HepG-2 cells
###end article-title 71
###begin article-title 72
Epidemiological characteristics and risk factors of hepatocellular carcinoma
###end article-title 72
###begin article-title 73
Hepatitis B and C viruses in the development of hepatocellular carcinoma
###end article-title 73
###begin article-title 74
Nonviral risk factors for hepatocellular carcinoma in a low-risk population, the non-Asians of Los Angeles County, California
###end article-title 74
###begin article-title 75
Sex hormones and liver cancer
###end article-title 75
###begin article-title 76
###xml 41 44 <span type="species:ncbi:10116">rat</span>
Cloning of a novel receptor expressed in rat prostate and ovary
###end article-title 76
###begin article-title 77
Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta
###end article-title 77
###begin article-title 78
Estrogen receptor transcription and transactivation: estrogen receptor alpha and estrogen receptor beta: regulation by selective estrogen receptor modulators and importance in breast cancer
###end article-title 78
###begin article-title 79
Estrogen receptor interaction with co-activators and co-repressors
###end article-title 79
###begin article-title 80
Estrogen receptor in the mammalian liver
###end article-title 80
###begin article-title 81
###xml 37 42 <span type="species:ncbi:9606">human</span>
Characterization and quantitation of human hepatic estrogen receptor
###end article-title 81
###begin article-title 82
###xml 43 48 <span type="species:ncbi:9606">human</span>
Characterization of estrogen receptor from human liver
###end article-title 82
###begin article-title 83
###xml 60 65 <span type="species:ncbi:9606">human</span>
Variant estrogen receptor messenger RNA species detected in human primary hepatocellular carcinoma
###end article-title 83
###begin article-title 84
Type of estrogen receptor determines response to antiestrogen therapy
###end article-title 84
###begin article-title 85
Natural history of inoperable hepatocellular carcinoma: estrogen receptors' status in the tumor is the strongest prognostic factor for survival
###end article-title 85
###begin article-title 86
Estrogen receptor classification for hepatocellular carcinoma: comparison with clinical staging systems
###end article-title 86
###begin article-title 87
Ligand-independent activation of estrogen receptor alpha by XBP-1
###end article-title 87
###begin article-title 88
###xml 43 48 <span type="species:ncbi:9606">human</span>
Identification of the sequences within the human complement 3 promoter required for estrogen responsiveness provides insight into the mechanism of tamoxifen mixed agonist activity
###end article-title 88
###begin article-title 89
Attenuation of estrogen receptor alpha-mediated transcription through estrogen-stimulated recruitment of a negative elongation factor
###end article-title 89
###begin article-title 90
A superfamily of potentially oncogenic hormone receptors
###end article-title 90
###begin article-title 91
###xml 66 72 <span type="species:ncbi:10090">murine</span>
Cloning, chromosomal localization, and functional analysis of the murine estrogen receptor beta
###end article-title 91
###begin article-title 92
###xml 30 47 <span type="species:ncbi:10407">hepatitis B virus</span>
Interferon gene transfer by a hepatitis B virus vector efficiently suppresses wild-type virus infection
###end article-title 92
###begin article-title 93
Identification and characterization of estrogen receptor variants in prostate cancer cell lines
###end article-title 93
###begin article-title 94
BRCA1-induced large-scale chromatin unfolding and allele-specific effects of cancer-predisposing mutations
###end article-title 94
###begin article-title 95
Characterization of the 'estrogenicity' of tamoxifen and raloxifene in HepG2 cells: regulation of gene expression from an ERE controlled reporter vector versus regulation of the endogenous SHBG and PS2 genes
###end article-title 95
###begin article-title 96
###xml 4 21 <span type="species:ncbi:10407">hepatitis B virus</span>
###xml 143 160 <span type="species:ncbi:10407">hepatitis B virus</span>
The hepatitis B virus encoded oncoprotein pX amplifies TGF-beta family signaling through direct interaction with Smad4: potential mechanism of hepatitis B virus-induced liver fibrosis
###end article-title 96
###begin article-title 97
###xml 0 17 <span type="species:ncbi:10407">Hepatitis B virus</span>
Hepatitis B virus X protein associated with UV-DDB1 induces cell death in the nucleus and is functionally antagonized by UV-DDB2
###end article-title 97
###begin article-title 98
###xml 80 84 <span type="species:ncbi:10090">mice</span>
Estrogen receptor transcription and transactivation: estrogen receptor knockout mice: what their phenotypes reveal about mechanisms of estrogen action
###end article-title 98
###begin article-title 99
###xml 34 39 <span type="species:ncbi:9606">human</span>
Connections and regulation of the human estrogen receptor
###end article-title 99
###begin article-title 100
###xml 83 88 <span type="species:ncbi:9606">human</span>
The estrogen receptor variant lacking exon 5 has dominant negative activity in the human breast epithelial cell line HMT-3522S1
###end article-title 100
###begin article-title 101
A tumor-specific truncated estrogen receptor splice variant enhances estrogen-stimulated gene expression
###end article-title 101
###begin article-title 102
The estrogen receptor (ER)alpha variant Delta5 exhibits dominant positive activity on ER-regulated promoters in endometrial carcinoma cells
###end article-title 102
###begin article-title 103
###xml 0 17 <span type="species:ncbi:10407">Hepatitis B virus</span>
Hepatitis B virus pX targets TFIIB in transcription coactivation
###end article-title 103
###begin article-title 104
###xml 4 21 <span type="species:ncbi:10407">hepatitis B virus</span>
The hepatitis B virus X protein targets the basic region-leucine zipper domain of CREB
###end article-title 104
###begin article-title 105
###xml 0 17 <span type="species:ncbi:10407">Hepatitis B virus</span>
Hepatitis B virus X protein enhances transcriptional activity of hypoxia-inducible factor-1alpha through activation of mitogen-activated protein kinase pathway
###end article-title 105
###begin article-title 106
###xml 0 17 <span type="species:ncbi:10407">Hepatitis B virus</span>
Hepatitis B virus X protein induces angiogenesis by stabilizing hypoxia-inducible factor-1alpha
###end article-title 106
###begin article-title 107
###xml 0 17 <span type="species:ncbi:10407">Hepatitis B virus</span>
Hepatitis B virus X protein is essential for the activation of Wnt/beta-catenin signaling in hepatoma cells
###end article-title 107
###begin article-title 108
###xml 0 17 <span type="species:ncbi:10407">Hepatitis B virus</span>
Hepatitis B virus X protein modulates peroxisome proliferator-activated receptor gamma through protein-protein interaction
###end article-title 108
###begin article-title 109
NURD, a novel complex with both ATP-dependent chromatin-remodeling and histone deacetylase activities
###end article-title 109
###begin article-title 110
BRCA1 mediates ligand-independent transcriptional repression of the estrogen receptor
###end article-title 110
###begin article-title 111
###xml 33 41 <span type="species:ncbi:9606">patients</span>
Controlled trial of tamoxifen in patients with advanced hepatocellular carcinoma
###end article-title 111
###begin article-title 112
Tamoxifen in treatment of hepatocellular carcinoma: a randomised controlled trial. CLIP Group (Cancer of the Liver Italian Programme).
###end article-title 112
###begin article-title 113
Tamoxifen in the treatment of hepatocellular carcinoma: 5-year results of the CLIP-1 multicentre randomised controlled trial
###end article-title 113
###begin article-title 114
High-dose tamoxifen in the treatment of inoperable hepatocellular carcinoma: a multicenter randomized controlled trial
###end article-title 114
###begin article-title 115
Histone deacetylase as a therapeutic target
###end article-title 115
###begin article-title 116
Inhibitors of histone deacetylase as new anticancer agents
###end article-title 116
###begin article-title 117
Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors
###end article-title 117
###begin article-title 118
The histone-deacetylase inhibitor Trichostatin A blocks proliferation and triggers apoptotic programs in hepatoma cells
###end article-title 118
###begin article-title 119
###xml 115 120 <span type="species:ncbi:9606">human</span>
Histone deacetylase inhibitor trichostatin A induces cell-cycle arrest/apoptosis and hepatocyte differentiation in human hepatoma cells
###end article-title 119
###begin title 120
Figures and Tables
###end title 120
###begin p 121
###xml 87 88 75 76 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 418 419 379 380 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 567 568 520 521 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 584 585 537 538 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 587 595 540 548 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">In vitro</italic>
###xml 717 719 658 660 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">35</sup>
###xml 776 777 713 714 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 883 884 820 821 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 886 893 823 830 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">In vivo</italic>
###xml 1039 1040 960 961 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
ERDelta5 represses ERalpha transcriptional activity through interaction with ERalpha. (A) ERDelta5 represses transcription of the ERE-Luc, pS2-Luc and C3-Luc reporters. HepG2 cells were co-transfected with 0.5 microg of the expression vector for ERDelta5, 0.5 microg of the expression plasmid for ERalpha and 0.2 microg of various luciferase reporter plasmids in the absence or presence of 10 nM of 17beta-estradiol (E2). The luciferase activity obtained on transfection of the respective luciferase reporter and ERalpha without exogenous ERDelta5 in the absence of E2 was set as 1. (B) In vitro interaction of ERDelta5 with ERalpha. Glutathione-Sepharose beads bound with GST-ERalpha or with GST were incubated with 35S-labeled ERDelta5 in the absence or presence of 100 nM E2. After washing the beads, the bound proteins were eluted and subjected to SDS-PAGE and autoradiography. (C) In vivo interaction of ERDelta5 with ERalpha. ERalpha and FLAG-tagged ERDelta5 were co-transfected into HepG2 cells in the presence or absence of 10 nM E2. Cell lysates were immunoprecipitated (IP) by anti-FLAG M2 monoclonal antibody (Sigma), and the precipitates were then immunoblotted (IB) with anti-ERalpha polyclonal antibody (Santa Cruz Biotech).
###end p 121
###begin p 122
###xml 75 76 71 72 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 288 289 276 277 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 404 405 388 389 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 421 422 405 406 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 661 662 637 638 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 949 950 909 910 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 962 963 922 923 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</bold>
###xml 985 986 941 942 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E</bold>
###xml 1026 1027 982 983 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1169 1170 1121 1122 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
HBx inhibits ERalpha-mediated transactivation function in hepatoma cells. (A) HepG2 cells were co-transfected with 0.2 microg of ERE-Luc, 50 ng of the expression plasmid for ERalpha and increasing amounts of the expression plasmid for FLAG-tagged HBx in the absence or presence of 10 nM E2. The luciferase activity obtained on transfection of ERE-Luc and ERalpha without exogenous HBx in the absence of E2 was set as 1. (B) Immunoblotting showing the ERalpha and HBx levels in HepG2 cells. Cells were transfected as in (A). Whole cell extracts were prepared from the cells transfected with 2.0 microg of the expression plasmid for HBx in the presence of 10 nM E2, and were detected with anti-ERalpha (Santa Cruz Biotech), anti-FLAG (Sigma) or anti-GAPDH (Biogenesis) antibody. (C-E) HepG2 cells were co-transfected with 50 ng of the expression plasmid for ERalpha, 1.0 microg of the expression plasmid for FLAG-tagged HBx, and 0.2 microg of C3-Luc (C), pS2-Luc (D) or pS2DeltaERE-Luc (E), in the absence or presence of 10 nM E2. The luciferase activity obtained on transfection of the respective luciferase reporter without exogenous ERalpha and HBx in the absence of E2 was set as 1.
###end p 122
###begin p 123
###xml 322 323 298 299 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 334 335 310 311 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 347 348 323 324 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 370 371 342 343 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</bold>
###xml 411 412 383 384 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 564 565 528 529 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 581 582 545 546 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E</bold>
###xml 863 864 811 812 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 910 911 858 859 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1054 1055 994 995 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
HBx and ERDelta5 have additive effect on repression of specific ERalpha responsive gene transcription. (A-D) HepG2 cells were co-transfected with 50 ng of the expression plasmid for ERalpha, 1.0 microg of the expression plasmid for FLAG-tagged HBx, 50 ng of the expression plasmid for ERDelta5, and 0.2 microg of ERE-Luc (A), C3-Luc (B), pS2-Luc (C) or pS2DeltaERE-Luc (D), in the absence or presence of 10 nM E2. The luciferase activity obtained on transfection of the respective luciferase reporter without exogenous ERalpha, ERDelta5 and HBx in the absence of E2 was set as 1. (E) HepG2 cells were co-transfected with 0.2 microg of pS2-Luc, 50 ng of the expression plasmid for ERalpha, 1.0 microg of the expression plasmid for FLAG-tagged HBx and 50 ng of the expression vector for ERDelta5. Cells were then treated with control (0.1% ethanol) vehicle, 10 nM E2, 100 nM 4-hydroxytamoxifen (4-OHT) or 10 nM E2 plus 100 nM 4-OHT. The luciferase activity obtained on transfection of pS2-Luc without exogenous ERalpha, ERDelta5 and HBx in the absence of E2 was set as 1.
###end p 123
###begin p 124
###xml 27 35 23 31 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 40 47 36 43 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 50 51 46 47 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 85 93 77 85 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 137 139 129 131 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">35</sup>
###xml 254 255 242 243 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 289 296 273 280 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 578 579 554 555 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 624 631 596 603 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 875 876 843 844 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</bold>
###xml 1220 1221 1156 1157 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E</bold>
###xml 1406 1407 1334 1335 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1672 1673 1592 1593 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F</bold>
###xml 1767 1769 1683 1685 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">35</sup>
###xml 2238 2239 2146 2147 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G</bold>
###xml 2372 2374 2276 2278 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">35</sup>
###xml 663 666 <span type="species:ncbi:10407?0.9699783742526397">HBV</span>
###xml 676 683 <span type="species:ncbi:9606">patient</span>
HBx interacts with ERalpha in vitro and in vivo. (A) Interaction of HBx with ERalpha in vitro. A GST pull-down assay was performed using 35S-labeled ERalpha, and GST or GST-HBx. The bound proteins were subjected to SDS-PAGE followed by autoradiography. (B) Interaction of HBx with ERalpha in vivo. ERalpha and FLAG-tagged HBx or empty vector were co-transfected into HepG2 cells. Cell lysates were immunoprecipitated (IP) by anti-FLAG M2 monoclonal antibody (Sigma), and the precipitates were then immunoblotted (IB) with anti-ERalpha polyclonal antibody (Santa Cruz Biotech). (C) Interaction of endogenous HBx with ERalpha in vivo. Liver tissue extracts from an HBV positive patient were immunoprecipitated with either anti-ERalpha polyclonal antibody or preimmune control serum (Santa Cruz Biotech). The precipitates were analyzed by immunoblot using anti-HBx (Chemicon). (D) Effect of ERDelta5 on the interaction between HBx and ERalpha. HepG2 cells were co-transfected with 2 microg ERalpha, 4 microg FLAG-tagged HBx and increasing amounts of ERDelta5 (2 and 4 microg). Cell lysates were immunoprecipitated by anti-FLAG monoclonal antibody, and the precipitates were detected with anti-ERalpha polyclonal antibody. (E) Co-localization of HBx and ERalpha in HepG2 cells. Cells were transfected with EGFP-tagged HBx and RFP-tagged ERalpha or empty vector (RFP) as indicated, and were treated with 10 nM E2 for 24 h. The images were captured by confocal immunofluorescence microscopy. HBx localization is shown with EGFP (green) and ERalpha is seen with RFP (red). The nuclei were stained with DAPI (blue). Co-localization of HBx with ERalpha is shown in merged images. (F) Mapping of the ERalpha interaction region in HBx. A GST pull-down assay was performed using 35S-labeled ERalpha and GST-HBx(1-72), GST-HBx(73-120), GST-HBx(121-154), GST-HBx(1-143), GST-HBx(52-154) and full-length GST-HBx(1-154) or GST. Schematic diagram of the HBx deletion constructs used is shown at the top, the binding of ERalpha to different regions of HBx is demonstrated in the middle, and SDS-PAGE analysis of the purified GST-fusion proteins is shown at the bottom. Asterisks indicate the positions of the expected purified GST or GST-fusion proteins. (G) Mapping of the HBx interaction region in ERalpha. A GST pull-down assay was performed using full-length GST-HBx(1-154) or GST, and 35S-labeled full-length ERalpha (1-595), ERalpha (1-185), ERalpha (180-282), ERalpha (282-595), ERalpha (302-595) or ERDelta5. Schematic diagram of the ERalpha deletion constructs used is shown at the top.
###end p 124
###begin p 125
###xml 95 96 91 92 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 378 379 358 359 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 382 383 362 363 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 530 531 506 507 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 640 641 616 617 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
The HBx deletion mutant abolishes HBx-induced repression of ERalpha transcriptional activity. (A) Luciferase reporter assays with the HBx deletion mutants. HepG2 cells were co-transfected with 0.2 microg of ERE-LUC, 50 ng of the expression plasmid for ERalpha and 1.0 microg of the expression vector for FLAG-tagged HBx or HBx(Delta73-120), in the presence or absence of 10 nM E2. (B) Western blotting showing expression of FLAG-tagged HBx and HBx(Delta73-120). Cells were transfected as in (A). Cell extracts were prepared from E2-treated cells, and equivalent amounts of each extract were detected with anti-FLAG or anti-GAPDH antibody. (C) The HBx deletion mutant abolishes the HBx-ERalpha interaction. HepG2 cells were co-transfected with the expression plasmid for ERalpha and the expression vector for FLAG-tagged HBx or HBx(Delta73-120). Cell lysates were immunoprecipitated by anti-FLAG, and the precipitates were probed with anti-ERalpha.
###end p 125
###begin p 126
###xml 45 46 41 42 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 78 86 74 82 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 124 126 120 122 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">35</sup>
###xml 192 193 184 185 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 227 234 215 222 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 479 480 467 468 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 524 531 508 515 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 771 772 751 752 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</bold>
###xml 1060 1066 <span type="species:ncbi:9986">rabbit</span>
HBx forms a complex with ERalpha and HDAC1. (A) Association of HBx with HDAC1 in vitro. GST-HBx and GST were incubated with 35S-labeled ERalpha, and a GST pull-down assay was then performed. (B) Association of HBx with ERalpha in vivo. HepG2 cells were transiently transfected with HA-tagged HDAC1 and FLAG-tagged HBx or control vector. Immunoprecipitation (IP) was performed using anti-FLAG monoclonal antibody; immunoblotting (IB) was performed with the indicated antibodies. (C) HBx interacts with both HDAC1 and ERalpha in vivo. HepG2 cells were co-transfected with ERalpha, HA-tagged HDAC1, and FLAG-tagged HBx or control vector. The cell extracts were immunoprecipitated with anti-FLAG monoclonal antibody followed by immunoblotting with the indicated antibodies. (D) HBx, ERalpha and HDAC1 forms a ternary complex. HepG2 cells were transfected as in (C). The cell extracts were immunoprecipitated with anti-FLAG antibody. Immune complexes were eluted with FLAG peptide and re-immunoprecipitated (re-IP) using anti-ERalpha polyclonal antibody and normal rabbit serum as a negative control. The resulting precipitates were resolved by SDS-PAGE followed by immunoblotting with the indicated antibodies.
###end p 126
###begin p 127
###xml 372 373 356 357 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 515 516 495 496 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
Treatment of hepatoma cells with the specific HDAC inhibitor TSA causes a drastic relieving of HBx-induced repression of ERalpha transactivation. HepG2 cells co-transfected with 0.2 microg of the ERE-Luc reporter, 50 ng of the expression vector for ERalpha, 1.0 microg of the expression plasmid for HBx. Cells were then treated with control (0.1% ethanol) vehicle, 10 nM E2 or 100 nM TSA as indicated. The luciferase activity obtained on transfection of ERE-Luc and ERalpha without exogenous HBx in the absence of E2 and TSA was set as 1.
###end p 127

